Humira

Under Amgen and AbbVie agreement, rival drug to AbbVie's Humira expected to launch in 2023
Marketwatch
Thu, 09/28/17 - 09:50 am
Amgen
AbbVie
Humira
Amgevita
biosimilars
drug launches
AbbVie's Unfazed by the Risk of Generic Humira
Motley Fool
Mon, 09/25/17 - 09:45 am
AbbVie
generics
Humira
AbbVie’s top execs paint a rosy pic of the mega-blockbuster future looming for Humira and PhIII drugs
Endpoints
Fri, 09/22/17 - 09:19 am
AbbVie
Humira
Rick Gonzalez
Which of These 5 Will Be the Best-Selling Drug Worldwide in 2020?
Motley Fool
Sat, 09/16/17 - 12:01 pm
AbbVie
Humira
Celgene
Revlimid
Bristol-Myers Squibb
Opdivo
Merck
Keytruda
Biogen
aducanumab
This Shield of Patents Protects the World’s Best-Selling Drug
Bloomberg
Fri, 09/8/17 - 09:25 am
patents
AbbVie
Humira
Biogen, Samsung Humira copy wins EU approval
Fierce Pharma
Fri, 08/25/17 - 09:52 am
Biogen
Samsung Bioepis
Europe
Humira
AbbVie
Imraldi
biosimilars
The decade's top 10 patent losses, worth a whopping $915B in lifetime sales
Fierce Pharma
Thu, 08/17/17 - 10:36 am
patents
AbbVie
Humira
Pfizer
Lipitor
Norvasc
GSK
Advair
Sanofi
Lantus
JNJ
Remicade
AstraZeneca
Crestor
Nexium
Amgen
Neulasta
Novartis
Diovan
Humira may spend most on TV, but Xeljanz, Taltz and Breo notch highest view rates
Fierce Pharma
Thu, 08/10/17 - 10:47 am
Humira
Xeljanz
Taltz
Breo
drug ads
television ads
DTC ads
AbbVie confident in strategy as Humira mints money
BioPharma Dive
Sat, 07/29/17 - 09:44 am
AbbVie
Humira
Novartis stocks drug cabinet with "Big-3" arthritis blockbusters
Yahoo/Reuters
Fri, 07/14/17 - 07:58 am
Novartis
rheumatoid arthritis
generics
Sandoz
Amgen
Enbrel
JNJ
Remicade
AbbVie
Humira
Key Humira patent gets struck down for the second time in as many months
Fierce Pharma
Sun, 07/9/17 - 11:38 am
Humira
patents
AbbVie
Boehringer Ingelheim
Coherus Biosciences
Lilly’s Olumiant, spurned by FDA, gets nod from NICE
Fierce Pharma
Sat, 07/1/17 - 09:26 am
FDA
NICE
Europe
Eli Lilly
olumiant
rheumatoid arthritis
Humira
The 9 Best-Selling Prescription Drugs in 2016 (Each One Topped $6 Billion)
Motley Fool
Fri, 06/30/17 - 11:06 am
prescription data
Sanofi
Lantus
Roche
Herceptin
Avastin
Celgene
Revlimid
JNJ
Merck
Remicade
Biogen
Rituxan
Amgen
Enbrel
Gilead Sciences
Harvoni
AbbVie
Humira
[video]Will AbbVie Outsmart Biosimilars, and Can Clovis Win the PARP Race?
Motley Fool
Tue, 06/27/17 - 09:45 am
AbbVie
biosimilars
Humira
Clovis Oncology
Rubraca
Novartis
Regeneron
Eylea
EMA Recommends New HCV, Cancer and MS Drugs for Approval
RAPS.org
Sat, 06/24/17 - 09:11 am
Europe
EMA
hepatitis C
multiple sclerosis
breast cancer
renal cell carcinoma
AbbVie
Maviret
Gilead Sciences
Vosevi
Biogen
Amgen
Samsung Bioepis
biosimilars
Humira
Novartis
Kisqali
EUSA
Fotivda
AbbVie's Eagerly Anticipated Followup to Humira Is Coming: What You Need to Know
Motley Fool
Fri, 06/23/17 - 03:37 pm
AbbVie
Humira
Upadacitinib
JAK inhibitors
autoimmune disease
AbbVie Stock Just Hit a 52-Week High: Here's Why It Should Go Even Higher
Motley Fool
Mon, 06/19/17 - 07:16 am
AbbVie
Humira
Key Humira patent goes down via IPR—but biosims makers shouldn't celebrate yet, analysts warn
Fierce Pharma
Thu, 05/18/17 - 12:09 am
Humira
patents
AbbVie
biosimilars
AbbVie Reports Humira Sales Growth in 1st Quarter
Yahoo/GuruFocus
Sun, 04/30/17 - 12:49 pm
AbbVie
Humira
earnings
Lilly and Incyte's Loss Is AbbVie and Regeneron's Gain
Motley Fool
Mon, 04/17/17 - 12:09 pm
Eli Lilly
Inctye
AbbVie
Regeneron
rheumatoid arthritis
FDA
baricitinib
Humira

Pages